Alpa Laboratorie

ALPA06 May 2024

Pharmaceuticals

₹

-0.50 (-0.53%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Alpa Laboratorie

Alpa Laboratorie

Pharmaceuticals

ALPA06 May 2024

₹

-0.50 (-0.53%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
01-Feb-2024	BC	ALPA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve to consider the Financial Results for th	13-Feb-2024
26-Oct-2023	BC	ALPA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve the Standalone and Consolidated Unaudite	07-Nov-2023
05-Sep-2023	BC	Annual Report for the Financial Year 2022-23. Intimation of the Book Closure for AGM to be held on 29th September, 2023. (As Per BSE Announcement dated on 09.09.2023) Outcome of AGM (As P	29-Sep-2023
29-Sep-2023	BC	Outcome of AGM	26-Sep-2023
09-Sep-2023	BC	Intimation of the Book Closure for AGM to be held on 29th September, 2023.	22-Sep-2023

No Rights has been declared by ALPA

Book Closure

Record Date	Split Date	Purpose
13-Feb-2024	-	ALPA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve to consider the Financial Results for th
07-Nov-2023	-	ALPA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve the Standalone and Consolidated Unaudite
29-Sep-2023	-	Annual Report for the Financial Year 2022-23. Intimation of the Book Closure for AGM to be held on 29th September, 2023. (As Per BSE Announcement dated on 09.09.2023) Outcome of AGM (As P
26-Sep-2023	-	Outcome of AGM
22-Sep-2023	01 Jan'1900	Intimation of the Book Closure for AGM to be held on 29th September, 2023.

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Alpa Laboratories Ltd ₹94.25(-0.50/-0.53%)	94.25	-0.50	199.35	52.97	11.15	1.30
Astrazeneca Pharma India Ltd ₹5,435.00(+10.55/0.19%)	5,435.00	+10.55	13,561.13	71.45	85.02	20.71
Bliss GVS Pharma Ltd ₹112.95(-6.15/-5.16%)	112.95	-6.15	1,246.87	56.07	18.27	1.28
Cipla Ltd ₹1,421.80(-2.95/-0.21%)	1,421.80	-2.95	115,033.60	54.70	34.98	4.44
Amrutanjan Health Care Ltd ₹754.80(-20.70/-2.67%)	754.80	-20.70	2,242.02	27.78	50.95	8.56
Abbott India Ltd ₹25,789.75(-354.70/-1.36%)	25,789.75	-354.70	55,556.96	15.92	48.50	17.87

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	27.31	32.39	25.43	29.16	27.31	13.54
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	27.31	32.39	25.43	29.16	27.31	13.54
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	3.55	2.95	4.47	-0.76	2.69	6.38
Total Income	30.86	35.35	29.90	28.40	30.01	19.92
Total Expenditure	24.85	29.08	26.58	19.90	24.69	19.28
PBIDT	6.01	6.27	3.32	8.50	5.32	0.64
Interest	0.03	0.04	0.02	0.04	0.07	0.08
PBDT	5.98	6.23	3.30	8.46	5.25	0.56
Depreciation	0.66	0.49	0.28	0.53	0.10	0.36
Tax	0.00	0.00	0.00	3.60	0.00	0.00
Deferred Tax	0.79	0.00	0.00	-0.29	0.00	0.00
Reported Profit After Tax	4.53	5.74	3.03	4.62	5.14	0.20
Extra-ordinary Items	0.02	0.00	0.03	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	4.51	5.74	3.00	4.62	5.14	0.20

EPS (Unit Curr.)	2.15	2.75	1.44	2.09	2.45	0.10
EPS (Adj) (Unit Curr.)	2.15	2.75	1.44	2.09	2.45	0.10
Calculated EPS (Unit Curr.)	2.15	2.73	1.44	2.20	2.44	0.09
Calculated EPS (Adj) (Unit Curr.)	2.15	2.73	1.44	2.20	2.44	0.09
Calculated EPS (Ann.) (Unit Curr.)	8.61	10.91	5.75	8.79	9.78	0.38
Calculated EPS (Adj) (Ann.) (Unit Curr.)	8.61	10.91	5.75	8.79	9.78	0.38
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	21.04	21.04	21.04	21.04	21.04	21.04
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	22.01	19.36	13.06	29.15	19.48	4.73
PBDTM(%)	21.90	19.23	12.98	29.01	19.22	4.14
PATM(%)	16.59	17.72	11.92	15.84	18.82	1.48

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	27.31	32.39	25.43	29.16	27.31	13.54
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	27.31	32.39	25.43	29.16	27.31	13.54
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	3.55	2.95	4.47	-0.69	2.67	6.33
Total Income	30.86	35.35	29.90	28.47	29.98	19.88
Total Expenditure	24.88	29.04	26.57	19.95	24.69	19.24
PBIDT	5.98	6.31	3.33	8.52	5.30	0.64
Interest	0.02	0.02	0.02	0.04	0.07	0.08
PBDT	5.96	6.28	3.31	8.49	5.22	0.56
Depreciation	0.66	0.49	0.28	0.53	0.10	0.36
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	0.00	0.00	0.00	3.60	0.00	0.00
Deferred Tax	0.79	0.00	0.00	-0.29	0.00	0.00
Reported Profit After Tax	4.51	5.79	3.03	4.65	5.12	0.20
Minority Interest After NP	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit after Minority Interest	4.51	5.79	3.03	4.65	5.12	0.20

Extra-ordinary Items	0.01	0.00	0.03	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	4.50	5.79	3.00	4.65	5.12	0.20

EPS (Unit Curr.)	2.17	2.75	1.44	2.12	2.43	0.10
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	21.04	21.04	21.04	21.04	21.04	21.04

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	21.90	19.48	13.09	29.22	19.41	4.73
PBDTM(%)	21.82	19.39	13.02	29.12	19.11	4.14
PATM(%)	16.51	17.88	11.92	15.95	18.75	1.48

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	21.04	21.04	21.04	21.04	21.04	21.04
Reserves Total	123.49	110.60	96.48	89.19	85.09	82.20
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	144.53	131.64	117.52	110.23	106.13	103.24
Secured Loans	1.07	4.47	0.01	0.41	1.67	5.98
Unsecured Loans	1.53	1.38	0.18	0.00	0.00	0.00
Total Debt	2.60	5.85	0.19	0.41	1.67	5.98
Total Liabilities	147.13	137.49	117.71	110.64	107.80	109.22
APPLICATION OF FUNDS :
Gross Block	33.46	34.41	30.64	30.01	28.74	28.01
Less : Accumulated Depreciation	26.42	25.09	23.43	23.61	22.98	21.89
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	7.04	9.32	7.21	6.40	5.76	6.12
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	0.00	1.57	0.81	0.12	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	89.60	85.73	61.93	67.61	59.43	41.34
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	12.64	15.46	16.56	12.55	14.04	13.72
Sundry Debtors	46.73	38.04	35.43	24.59	29.81	25.44
Cash and Bank	8.79	1.31	10.24	5.92	0.88	21.29
Loans and Advances	8.02	13.30	16.96	11.94	18.18	17.92
Total Current Assets	76.19	68.11	79.18	55.00	62.91	78.36
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	24.42	22.43	30.34	17.59	18.79	16.30
Provisions	3.68	2.65	1.96	2.97	2.24	1.07
Total Current Liabilities	28.10	25.08	32.30	20.56	21.03	17.37
Net Current Assets	48.08	43.03	46.88	34.44	41.89	61.00
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.00	0.00	0.00	0.93	0.17	0.76
Deferred Tax Liability	2.28	2.57	0.22	0.00	0.00	0.00
Net Deferred Tax	-2.28	-2.57	-0.22	0.93	0.17	0.76
Total Assets	142.44	135.51	117.38	110.20	107.37	109.22
Contingent Liabilities	3.18	5.21	5.21	5.68	4.07	3.11

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	21.04	21.04	21.04	21.04	21.04	21.04
Reserves Total	113.54	100.69	86.60	79.33	77.45	76.51
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	134.58	121.73	107.64	100.37	98.49	97.55
Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
Secured Loans	0.78	4.47	0.01	0.41	1.67	5.98
Unsecured Loans	1.53	1.38	0.18	0.00	0.00	0.00
Total Debt	2.31	5.85	0.19	0.41	1.67	5.98
Policy Holders Fund	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	136.89	127.58	107.83	100.78	100.16	103.53
APPLICATION OF FUNDS :
Gross Block	33.46	34.41	30.64	30.01	38.86	38.12
Less: Accumulated Depreciation	26.42	25.09	23.43	23.61	31.08	27.96
Less: Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	7.04	9.32	7.21	6.40	7.78	10.16
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	0.00	1.58	0.81	0.12	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	78.45	74.63	50.84	56.58	48.59	30.56
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	12.64	15.46	16.56	12.55	14.04	13.72
Sundry Debtors	46.73	38.04	35.43	24.59	30.00	26.02
Cash and Bank	8.81	1.58	10.51	6.17	0.90	21.34
Loans and Advances	8.91	14.24	17.89	12.86	19.19	18.96
Total Current Assets	77.10	69.31	80.39	56.17	64.13	80.04
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	24.42	22.44	30.35	17.59	18.82	16.93
Provisions	5.97	5.22	1.97	2.97	2.24	1.07
Total Current Liabilities	30.39	27.66	32.32	20.57	21.06	18.00
Net Current Assets	46.71	41.65	48.08	35.61	43.07	62.04
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.00	0.00	0.00	0.93	0.17	0.76
Deferred Tax Liability	0.00	0.00	0.22	0.00	0.00	0.00
Net Deferred Tax	0.00	0.00	-0.22	0.93	0.17	0.76
Other Assets	4.67	1.98	0.34	0.45	0.43	0.00
Total Assets
Contingent Liabilities	3.18	5.21	5.21	5.68	4.07	3.11

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	2.65	10.85	5.92	0.88	21.29
Net Cash from Operating Activities	8.82	2.20	-1.47	17.66	-0.68
Net Cash Used In Investing Activities	2.14	-15.61	5.82	-11.27	-14.95
Net Cash Used In Financing Activities	-3.48	5.41	-0.03	-1.35	-4.78
Net Inc./Dec In Cash And Cash Equivalents	7.48	-7.99	4.32	5.03	-20.40
Cash And Cash Equivalents At End Of The Year	10.13	2.85	10.24	5.92	0.88

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

57.29%

FII Shareholding

0.50%

DII Shareholding

0.00%

Public Shareholding

42.20%

**Promoter pledged shareholding 57.29%

About Alpa Laboratories Ltd

Alpa Laboratories Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 199.35 crores. It has reported a sales of Rs. 27.31 crores and a net profit of Rs. 4.53 crores for the quarter ended December 2018. The company management includes Mahendra Singh Chawla, Mahendra Singh Chawla,Pravin C Shah,Sharad Chand Lunawat,Devendra Baheti,Krishna Das Malani,Paresh Chawla,Jyoti Jain,Swati Bagh,Vitthal Kothana,SUNIL VALECHA,Saket Baheti,Pratibha Lunawat (Alpa Laboratories Ltd) among others.

Chairman

Mahendra Singh Chawla

Registered office

33/2 Pigdamber,A B Road Rau,Indore,Madhya Pradesh,453446

FAX :91-731-4294444

Background

Incorporation Year1988

Face Value₹10

Market Lot1

How to buy Alpa Laboratorie shares on nse?

To buy Alpa Laboratorie shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Alpa Laboratorie share price today?

The Alpa Laboratorie shares price on nse is Rs.94.25 today.

What is the market cap of Alpa Laboratorie shares on BSE ?

The company has a market capitalization of Rs.199.35Cr

What is the PE & PB ratio of Alpa Laboratorie shares ?

PE is 11.15 and PB is 1.3

What is the 52 Week High and Low of Alpa Laboratorie shares?

Alpa Laboratorie stock price high: Rs.115 Alpa Laboratorie stock price low: Rs.55.1